Extracorporeal Treatment for Barbiturate Poisoning: Recommendations From the EXTRIP Workgroup

Imagem de Miniatura
Arquivos
art_MACTIER_Extracorporeal_Treatment_for_Barbiturate_Poisoning_Recommendations_From_the_2014.PDF (452.32 KB)
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO-ELSEVIER INC
Autores
MACTIER, Robert
LALIBERTE, Martin
MARDINI, Joelle
GHANNOUM, Marc
LAVERGNE, Valery
GOSSELIN, Sophie
HOFFMAN, Robert S.
NOLIN, Thomas D.
Citação
AMERICAN JOURNAL OF KIDNEY DISEASES, v.64, n.3, p.347-358, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup conducted a systematic review of barbiturate poisoning using a standardized evidence-based process to provide recommendations on the use of extracorporeal treatment (ECTR) in patients with barbiturate poisoning. The authors reviewed all articles, extracted data, summarized key findings, and proposed structured voting statements following a predetermined format. A 2-round modified Delphi method was used to reach a consensus on voting statements, and the RAND/UCLA Appropriateness Method was used to quantify disagreement. 617 articles met the search inclusion criteria. Data for 538 patients were abstracted and evaluated. Only case reports, case series, and nonrandomized observational studies were identified, yielding a low quality of evidence for all recommendations. Using established criteria, the workgroup deemed that long-acting barbiturates are dialyzable and short-acting barbiturates are moderately dialyzable. Four key recommendations were made. (1) The use of ECTR should be restricted to cases of severe long-acting barbiturate poisoning. (2) The indications for ECTR in this setting are the presence of prolonged coma, respiratory depression necessitating mechanical ventilation, shock, persistent toxicity, or increasing or persistently elevated serum barbiturate concentrations despite treatment with multiple-dose activated charcoal. (3) Intermittent hemodialysis is the preferred mode of ECTR, and multiple-dose activated charcoal treatment should be continued during ECTR. (4) Cessation of ECTR is indicated when clinical improvement is apparent. This report provides detailed descriptions of the rationale for all recommendations. In summary, patients with long-acting barbiturate poisoning should be treated with ECTR provided at least one of the specific criteria in the first recommendation is present. (C) 2014 by the National Kidney Foundation, Inc.
Palavras-chave
Barbiturates, poisoning, EXTRIP (Extracorporeal Treatments in Poisoning), recommendations, extracorporeal treatment, hemodialysis, dialyzability
URI
https://observatorio.fm.usp.br/handle/OPI/26868
Referências
  1. AGARWAL SK, 1993, INT J ARTIF ORGANS, V16, P20
  2. ALWALL N, 1953, ACTA MED SCAND, V147, P119
  3. Arriagada Tapia S, 1978, Rev Chil Pediatr, V49, P175
  4. BALME RH, 1962, BRIT MED J, P231
  5. BAMBAUER R, 1982, Intensivmedizin, V19, P79
  6. BARBER K, 1984, ARTIF ORGANS, V8, P229, DOI 10.1111/j.1525-1594.1984.tb04278.x
  7. BARBOUR BH, 1976, KIDNEY INT, V10, pS333
  8. BENTLEY C, 1979, J DIALYSIS, V3, P337, DOI 10.3109/08860227909063951
  9. BERMAN LB, 1956, JAMA-J AM MED ASSOC, V161, P820, DOI 10.1001/jama.1956.02970090046010
  10. BERMAN LB, 1964, NEW ENGL J MED, V270, P77, DOI 10.1056/NEJM196401092700204
  11. BIRD TD, 1968, NEUROLOGY, V18, P456, DOI 10.1212/WNL.18.5.456
  12. Bironneau E, 1996, RENAL FAILURE, V18, P299, DOI 10.3109/08860229609052800
  13. BISMUTH C, 1981, CLIN TOXICOL, V18, P1213, DOI 10.3109/00099308109035060
  14. BISMUTH C, 1976, EUR J TOXICOL ENV HY, V9, P55
  15. Bismuth C, 1980, Dev Toxicol Environ Sci, V8, P377
  16. Bjaeldager P A, 1983, Ugeskr Laeger, V145, P3653
  17. BOLDY DAR, 1986, Q J MED, V61, P997
  18. BOSL R, 1975, NEPHRON, V15, P151, DOI 10.1159/000180506
  19. Botti P, 2004, CLIN TOXICOL, V42, P518
  20. Bouma A W, 2004, Ned Tijdschr Geneeskd, V148, P1642
  21. BREIMER DD, 1977, CLIN PHARMACOKINET, V2, P93, DOI 10.2165/00003088-197702020-00002
  22. Bronstein AC, 2009, CLIN TOXICOL, V47, P911, DOI 10.3109/15563650903438566
  23. BROWN I A, 1954, Minn Med, V37, P650
  24. BRUNI J, 1984, CLIN NEUROPHARMACOL, V7, P1, DOI 10.1097/00002826-198403000-00001
  25. Cantrell FL, 2010, CLIN TOXICOL, V48, P849, DOI 10.3109/15563650.2010.512562
  26. Ciliberto G, 1982, RIV TOSSICOL SPER CL, V12, P161
  27. CODINA S, 1979, REV CLIN ESP, V152, P25
  28. COHAN SL, 1982, DRUG METAB REV, V13, P681, DOI 10.3109/03602538209011092
  29. CROME P, 1980, POSTGRAD MED J, V56, P763, DOI 10.1136/pgmj.56.661.763
  30. CRUZ IA, 1967, J AMER MED ASSOC, V202, P438, DOI 10.1001/jama.202.5.438
  31. DARNELL A, 1980, MED CLIN-BARCELONA, V75, P49
  32. DEGROOT G, 1979, VET HUM TOXICOL, V21, P8
  33. DEGROOT G, 1977, NETH J MED, V20, P142
  34. DEL GRECO F, 1962, Q Bull Northwest Univ Med Sch, V36, P306
  35. DOENICKE A, 1965, ACTA ANAESTH SCAND, P11
  36. DUERR F, 1965, Med Welt, V15, P755
  37. DURAKOVIC Z, 1986, Arhiv za Higijenu Rada i Toksikologiju, V37, P59
  38. Ebid AHIM, 2001, THER DRUG MONIT, V23, P209
  39. Falda Z, 1971, Pol Arch Med Wewn, V47, P167
  40. FANTOZZI R, 1981, Substance and Alcohol Actions-Misuse, V2, P55
  41. FERGUSON MJ, 1961, ANN INTERN MED, V54, P726, DOI 10.7326/0003-4819-54-4-726
  42. Frenia ML, 1996, J TOXICOL-CLIN TOXIC, V34, P169, DOI 10.3109/15563659609013766
  43. FRITZER W, 1965, Wien Z Inn Med, V46, P72
  44. GAL G, 1956, Orv Hetil, V97, P582
  45. GAL GEORG, 1965, Z GESAMTE INN MED GRENZ, V20, P304
  46. Garcia Perez JJ, 1980, REV CLIN ESP, V156, P413
  47. GELFAND MC, 1977, T AM SOC ART INT ORG, V23, P599
  48. Ghannoum M, 2012, CLIN J AM SOC NEPHRO, V7, P1682, DOI 10.2215/CJN.01940212
  49. GRABENSEE B, 1976, DEUT MED WOCHENSCHR, V101, P158, DOI 10.1055/s-0028-1104052
  50. HELLIWELL M, 1980, POSTGRAD MED J, V56, P363, DOI 10.1136/pgmj.56.655.363
  51. HENNEMANN H, 1976, DEUT MED WOCHENSCHR, V101, P155, DOI 10.1055/s-0028-1104051
  52. HERMS W, 1966, DEUT MED WOCHENSCHR, V91, P2007, DOI 10.1055/s-0028-1111630
  53. HILL JB, 1976, CLIN CHEM, V22, P754
  54. HOLZER P, 1987, ARCH TOXICOL, V60, P394, DOI 10.1007/BF00295761
  55. Hoyland K, 2013, BMJ CASE REP
  56. HUDSON JB, 1969, SOUTHERN MED J, V62, P457, DOI 10.1097/00007611-196904000-00019
  57. HURWICH BJ, 1974, ISRAEL J MED SCI, V10, P495
  58. IVERSEN BM, 1979, CLIN TOXICOL, V15, P139, DOI 10.3109/15563657908989859
  59. Jacobs F, 2004, NEPHROL DIAL TRANSPL, V19, P1663, DOI 10.1093/ndt/gfh221
  60. Janos L, 1977, Orv Hetil, V118, P277
  61. Jorgensen K A, 1978, Ugeskr Laeger, V140, P960
  62. Kamijo Y, 2002, VET HUM TOXICOL, V44, P348
  63. KENNEDY AC, 1969, LANCET, V1, P995
  64. KESSEL M, 1962, KLIN WOCHENSCHR, V40, P580, DOI 10.1007/BF01478632
  65. KEUSCHBECK M, 1980, SCHWEIZ MED WSCHR, V110, P1566
  66. Kirchmair W., 1981, MUNCH MED WSCHR, V123, P231
  67. KLINKMANN H, 1964, Dtsch Gesundheitsw, V19, P60
  68. Knutsen K M, 1979, Tidsskr Nor Laegeforen, V99, P172
  69. KOFFLER A, 1978, ARCH INTERN MED, V138, P1691, DOI 10.1001/archinte.138.11.1691
  70. KYLE LH, 1953, J CLIN INVEST, V32, P364, DOI 10.1172/JCI102747
  71. LAI CW, 1990, ARCH NEUROL-CHICAGO, V47, P66, DOI 10.1001/archneur.1990.00530010080024
  72. Lal R, 2006, AM J KIDNEY DIS, V48, pE13, DOI 10.1053/j.ajkd.2006.04.081
  73. LANDMANN J, 1959, Med Cir Farm, V21, P121
  74. LARCAN A, 1979, VET HUM TOXICOL, V21, P19
  75. Lavergne V, 2012, CLIN TOXICOL, V50, P403, DOI 10.3109/15563650.2012.683436
  76. LIN JL, 1995, ANN EMERG MED, V25, P75, DOI 10.1016/S0196-0644(95)70359-4
  77. LIN JL, 1994, BLOOD PURIFICAT, V12, P121, DOI 10.1159/000170156
  78. LINTON AL, 1964, LANCET, V1, P1008
  79. Logi G, 1969, ACTA ANAESTHESIOL S2, V20, P39
  80. LUBASH GD, 1962, ARCH INTERN MED, V110, P884, DOI 10.1001/archinte.1962.03620240066010
  81. MAHER J F, 1964, Ohio State Med J, V60, P235
  82. MANTZ JM, 1971, PRESSE MED, V79, P1243
  83. Mihic S, 2011, GOODMAN GILMANS PHAR, P457
  84. Morikawa N, 1992, JPN J CLIN PHARM THE, V23, P469
  85. Mowry JB, 2013, CLIN TOXICOL, V51, P949, DOI 10.3109/15563650.2013.863906
  86. MULLAN D, 1965, LANCET, V1, P705
  87. Musson V J, 1976, Nurs Times, V72, P1956
  88. PACH J, 1987, Polski Tygodnik Lekarski, V42, P333
  89. Palmer BF, 2000, AM J KIDNEY DIS, V36, P640, DOI 10.1053/ajkd.2000.16207
  90. Pedersen R S, 1978, Ugeskr Laeger, V140, P2430
  91. PENDER JC, 1957, ANN INTERN MED, V46, P997, DOI 10.7326/0003-4819-46-5-997
  92. POGGLITSCH H, 1965, Wien Med Wochenschr, V115, P308
  93. POND S, 1982, J TOXICOL-CLIN TOXIC, V19, P187, DOI 10.3109/15563658208990380
  94. POND SM, 1984, JAMA-J AM MED ASSOC, V251, P3104, DOI 10.1001/jama.251.23.3104
  95. PREMELCABIC A, 1973, THERAPIE, V28, P977
  96. Proudfoot AT, 2004, J TOXICOL-CLIN TOXIC, V42, P1, DOI 10.1081/CLT-120028740
  97. Puka J, 1975, Pol Tyg Lek, V30, P1583
  98. Quan DJ, 1998, J APPL THER RES, V2, P75
  99. RAPER S, 1982, ARCH TOXICOL, V49, P303, DOI 10.1007/BF00347878
  100. Roberts DM, 2011, BRIT J ANAESTH, V107, P820, DOI 10.1093/bja/aer317
  101. Roberts DM, 2011, CLIN TOXICOL, V49, P2, DOI 10.3109/15563650.2010.550582
  102. ROSENBAUM JL, 1971, NEW ENGL J MED, V284, P874, DOI 10.1056/NEJM197104222841603
  103. ROSENBAUM JL, 1970, T AM SOC ART INT ORG, V16, P134
  104. ROSENBAUM JL, 1976, KIDNEY INT, V10, pS341
  105. Rosland G A, 1967, Tidsskr Nor Laegeforen, V87, P20
  106. SAGRAVES R, 1983, DRUG INTEL CLIN PHAR, V17, P901, DOI 10.1177/106002808301701208
  107. SAMPSON I, 1983, MT SINAI J MED, V50, P283
  108. Sancak R, 1999, PEDIATR EMERG CARE, V15, P268
  109. Sanz Guajardo A, 1975, Rev Clin Esp, V136, P147
  110. SCHREINER GE, 1958, ARCH INTERN MED, V102, P896, DOI 10.1001/archinte.1958.00260230042007
  111. SCHREINER GE, 1971, T AM SOC ART INT ORG, V17, P513
  112. SETTER JG, 1966, ARCH INTERN MED, V117, P224, DOI 10.1001/archinte.117.2.224
  113. SETTER JG, 1964, T AM SOC ART INT ORG, V10, P340
  114. Shannon MW, 1997, ACAD EMERG MED, V4, P674, DOI 10.1111/j.1553-2712.1997.tb03758.x
  115. SKETRIS IS, 1984, PLASMA THER TRANSFUS, V5, P305
  116. SMOLLE KH, 1987, WIEN KLIN WOCHENSCHR, V99, P793
  117. Sorensen E, 1974, Ugeskr Laeger, V136, P1687
  118. Soylemezoglu O., 1993, International Urology and Nephrology, V25, P111, DOI 10.1007/BF02552263
  119. Srinivas S, 2004, INDIAN J CRIT CARE M, V8, P153
  120. Stein G, 1971, Z Arztl Fortbild (Jena), V65, P296
  121. Stein G, 1981, Z Gesamte Inn Med, V36, P963
  122. Susa S, 1968, Vojnosanit Pregl, V25, P252
  123. TERPLAN M, 1966, J AMER MED ASSOC, V198, P322, DOI 10.1001/jama.198.3.322
  124. Thompson Trevonne M, 2007, J Med Toxicol, V3, P31
  125. TORRENTE AD, 1979, NEPHRON, V24, P71
  126. TRAFFORD A, 1980, CLIN TOXICOL, V17, P547, DOI 10.3109/15563658008990005
  127. TRAFFORD JAP, 1977, BRIT MED J, V2, P1453, DOI 10.1136/bmj.2.6100.1453
  128. Vale J, 1999, J TOXICOL-CLIN TOXIC, V37, P731
  129. VALE JA, 1975, BRIT MED J, V1, P5, DOI 10.1136/bmj.1.5948.5
  130. van de Plas A, 2006, CLIN TOXICOL, V44, P93, DOI 10.1080/1556350500395040
  131. van Dijk B, 1979, Tijdschr Ziekenverpl, V32, P728
  132. VANHEIJST ANP, 1983, J TOXICOL-CLIN TOXIC, V20, P307, DOI 10.3109/15563658308990598
  133. Voigtmann R, 1976, Med Welt, V27, P752
  134. von Baeyer H, 1974, Dtsch Med Wochenschr, V99, P189
  135. Wehner J, 1991, Kinderarztl Prax, V59, P31
  136. WHANG R, 1970, CLIN TOXICOL, V3, P551, DOI 10.3109/15563657008990127
  137. WHITING EG, 1965, CALIF MED, V102, P367
  138. Wieth J O, 1966, Int Anesthesiol Clin, V4, P359
  139. ZAWADA ET, 1983, SOUTHERN MED J, V76, P6, DOI 10.1097/00007611-198301000-00003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/12